Additive Clinical Utility of Microsatellite Instability and Tumor Mutational Burden to Predict Immune Checkpoint Inhibitor Effectiveness in Metastatic Castration-Resistant Prostate Cancer.

doi:10.1158/1078-0432.CCR-25-2750

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Additive Clinical Utility of Microsatellite Instability and Tumor Mutational Burden to Predict Immune Checkpoint Inhibitor Effectiveness in Metastatic Castration-Resistant Prostate Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research - 17 Feb 2026

Sayegh Nicolas, Graf Ryon P, Swami Umang, Ozay Zeynep Irem, Hage Chehade Chadi, Elvin Julia A, Lin Douglas, Quintanilha Julia C F, Li Gerald, Bryce Alan H, McKay Rana R, Ross Jeffrey S, Zhang Tian, Agarwal Neeraj

Abstract excerpt

PURPOSE: Immune checkpoint inhibitors (ICI) have shown limited efficacy in unselected patients with metastatic castration-resistant prostate cancer (mCRPC). However, ICIs are approved for biomarker-defined subsets: microsatellite instability-high (MSI-H) and/or high tumor mutational burden (TMB-H). The efficacy of ICIs in TMB-H but not MSI-H disease remains unclear, and limited data exist evaluating ICI outcomes...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antibodies, Monoclonal, Humanized

Share to Biomarkers, Tumor

Share to Immune Checkpoint Inhibitors

Share to Microsatellite Instability

Share to Neoplasm Metastasis

Share to Prognosis

Share to Prostatic Neoplasms, Castration-Resistant

Source

Open in PubMed Open full text

Identifiers

PMID: 41342879
DOI: 10.1158/1078-0432.CCR-25-2750
PMCID: PMC13056297

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Additive Clinical Utility of Microsatellite Instability and Tumor Mutational Burden to Predict Immune Checkpoint Inhibitor Effectiveness in Metastatic Castration-Resistant Prostate Cancer.PMID 41342879Read ↗

Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer.Semantic proximity Read ↗

A Real-World Experience of Pembrolizumab Monotherapy in Microsatellite Instability-High and/or Tumor Mutation Burden-High Metastatic Castration-Resistant Prostate Cancer: Outcome AnalysisSemantic proximity Read ↗

Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer.Semantic proximity Read ↗

Comprehensive Analysis of Tumor Mutational Burden in Prostate Cancer: Multipublic Dataset Analysis.Semantic proximity Read ↗

Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA.Semantic proximity Read ↗

The Role of Histology-Agnostic Drugs in the Treatment of Metastatic Castration-Resistant Prostate Cancer.Semantic proximity Read ↗

Ipilimumab with nivolumab in molecularly selected patients with castration-resistant prostate cancer: primary analysis of the phase II INSPIRE trial.Semantic proximity Read ↗

Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial.Semantic proximity Read ↗

The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited.Semantic proximity Read ↗

Nivolumab in Patients with Metastatic Castration-Resistant Prostate Cancer with and without DNA Repair DefectsSemantic proximity Read ↗

Real-world insights from comprehensive genomic profiling in patients with metastatic castration-resistant prostate cancer.Semantic proximity Read ↗

BRCA1/2 and homologous recombination repair alterations in high- and low-volume metastatic hormone-sensitive prostate cancer: prevalence and impact on outcomes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.